Why Reckitt’s court win sent shares up 4% in a day

Most of the time a share price moves because of results, economic data, or a market-wide mood shift. Occasionally, however, the catalyst arrives from a courtroom. The Reckitt Benckiser story this week is a sharp reminder that legal cases can be just as powerful a force on a share price as a profits announcement — and that understanding why requires grasping a concept called litigation risk.

What Reckitt Benckiser is

Reckitt Benckiser is one of the most recognisable consumer goods companies in the world and a long-standing member of the FTSE 100. Its brands sit in millions of UK homes: Dettol disinfectant, Nurofen painkillers, Strepsils lozenges, Gaviscon indigestion remedy, Durex, and Vanish. The business operates in over 60 countries and employs roughly 40,000 people globally.

One of its divisions is Mead Johnson, a US infant nutrition business it acquired in 2017 for $16.6 billion. Mead Johnson makes Enfamil, one of the most widely used baby formula brands in the United States.

For the past several years, Mead Johnson has been the subject of a large body of litigation in American courts. Premature or ill babies fed certain formula products — including Enfamil and similar products made by competitor Abbott — later developed a serious bowel condition called necrotising enterocolitis, or NEC. Families and hospitals brought lawsuits claiming the formula caused or contributed to the illness. The number of cases grew into the hundreds, and they were eventually consolidated into a multidistrict litigation, or MDL, in a US federal court.

What litigation risk does to a share price

When a company faces hundreds of lawsuits with uncertain outcomes, investors face a problem: they do not know how much the company might eventually have to pay. The potential liability could range from very little (if juries consistently find in the company’s favour) to many billions (if the company loses case after case and faces large damages awards).

That uncertainty is itself damaging. Investors generally dislike not knowing. When they cannot put a realistic number on a risk, they apply a discount to the share price — a kind of built-in buffer against the worst case. This is what had been weighing on Reckitt shares throughout the NEC litigation period: not just the fear of losing, but the fog of not yet knowing.

You can see the same dynamic with pharmaceutical companies involved in drug safety claims, mining companies facing environmental suits, or technology firms dealing with regulatory investigations. The share price does not wait for the final outcome; it starts adjusting the moment the scale of the legal exposure becomes clearer. Understanding this is part of reading risk in any investment.

The bellwether verdict

A US federal MDL does not try every case individually at the start. Instead, both sides select a handful of representative cases — known as bellwether trials — to test the legal arguments before juries. The outcomes of these trials send a strong signal about how the remaining hundreds of cases are likely to be resolved, either through further court rulings or through a negotiated settlement.

On 2 September 2026, a jury in the US District Court for the Northern District of Illinois returned a unanimous verdict in favour of Mead Johnson in the first bellwether case. The company had argued that Enfamil preterm formula did not cause the child’s NEC diagnosis. The jury agreed.

Mead Johnson said after the ruling that there were currently no outstanding jury verdicts against it in the overall NEC litigation. That is significant: going into the verdict, investors had been pricing in at least some probability that the company would face costly judgments. The first bellwether win suggested the risk might be lower than feared.

Why shares jumped 4.3%

Reckitt shares rose 4.3% on the day of the verdict, to around 5,326p. On a company the size of Reckitt, that translates into billions of pounds added to the market capitalisation in a single session. The catalyst was the verdict — but another factor amplified the move.

On the same day, the investment bank JPMorgan upgraded its rating on Reckitt shares from “neutral” to “overweight”. In straightforward English: JPMorgan’s analysts shifted from saying “this share is fairly valued” to saying “this share is likely to outperform the market over the next year”.

Investment bank upgrades matter because large institutional investors — pension funds, insurance companies, sovereign wealth funds — pay close attention to analyst research. When a major bank raises its rating, it can prompt fund managers to buy shares they had previously been underweight in, creating genuine buying pressure. The combination of a positive legal verdict and a JPMorgan upgrade on the same morning was unusually powerful: it removed uncertainty and added positive buying momentum simultaneously.

This is a good illustration of why news can move a share price so sharply in a short period. When two pieces of positive news arrive together, the effect tends to compound rather than simply add up.

Why the shares did not recover fully

Even after the 4.3% jump, Reckitt shares stood at around 5,326p — still approximately 15% below their 52-week high of 6,253p. That gap tells you something important: one bellwether win reduces the uncertainty, but it does not end the story.

Hundreds of NEC cases remain pending in the MDL and in state courts across the United States. The verdict in this first bellwether was a positive data point, but future juries may decide differently. It is also possible that the remaining cases settle out of court — at some cost to Mead Johnson — rather than going to trial one by one.

What the market was effectively saying on 2 September is: we now think this litigation is less dangerous than we feared, but we do not yet know how it ends. The discount applied to the share price therefore narrowed, but did not disappear. That is how probability-weighted markets work: they price in the likelihood of outcomes, not just the best case or the worst case.

Three things this teaches you as an investor

The Reckitt story is a clean example of a pattern you will encounter with any company that carries significant legal exposure:

• Legal risk appears in the financial press as a headwind. If you read that a company “faces billions in potential legal claims,” the share price has almost certainly already adjusted downward to reflect some of that risk. When the risk resolves more favourably than feared — as Reckitt’s did on Tuesday — the share price often bounces sharply because the built-in discount is no longer needed.
• The source of a share price move matters as much as its size. A 4% single-day gain driven by a legal verdict and an analyst upgrade is quite different from a 4% gain driven by a profit beat. The former tells you about uncertainty lifting; the latter tells you about business performance improving. Both are important, but they have different implications for what might happen next.
• Relief rallies can still leave a long recovery ahead. Reckitt was still below its 52-week high despite the positive news. If you are analysing whether to hold or buy a company in similar circumstances, the question is not just whether today’s news was positive, but how much further uncertainty remains to be resolved.

If you hold shares in consumer goods companies — names like Reckitt, Unilever, or Haleon — within your virtual portfolio in the Challenge, results seasons and major legal events are the two moments to pay closest attention to. Both can shift a share’s price sharply and in ways that look counterintuitive unless you understand what markets are really reacting to.

A note on this story and investing

The NEC litigation involves serious harm to premature babies and to families. This article covers the story solely as a financial case study about how legal risk affects share prices. The outcome of any individual case has human significance that goes well beyond the movement of a share price, and it is worth keeping that in perspective when reading about lawsuits in a financial context.

FAQ

What is litigation risk?

Litigation risk is the possibility that a company faces financial penalties, compensation payments, or reputational damage as a result of lawsuits. When multiple similar cases are filed, the total potential liability can be large and uncertain. That uncertainty tends to weigh on a share price until verdicts start clarifying the likely outcome.

What is a multidistrict litigation (MDL)?

An MDL is a US legal procedure that consolidates many similar lawsuits into one federal court for the pre-trial stages. Bellwether trials are then chosen to test the arguments on both sides. Their outcomes inform how likely the remaining cases are to settle and at what cost, making them closely watched by investors and analysts.

What is an analyst upgrade and why does it move shares?

Investment banks publish ratings on shares — typically “buy,” “hold,” or “sell” (or equivalents such as “overweight” and “neutral”). An upgrade means an analyst has raised their rating, usually because they now expect the share to outperform. Upgrades from large banks like JPMorgan matter because their recommendations influence institutional investors who manage very large funds.

If Reckitt won the case, why did shares stay below their 52-week high?

Winning one bellwether trial reduces uncertainty but does not eliminate it. Hundreds of similar NEC cases remain pending. Until those are resolved — through further verdicts or settlement — litigation risk still exists, just at a lower level. Share prices reflect probability-weighted expectations, so a reduction in risk is rewarded with a partial recovery, but full recovery typically waits for full resolution.